creatine has been researched along with Cancer of Prostate in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The (choline + creatine)/ citrate values in regions of histologically confirmed benign prostatic hyperplasia (0." | 3.69 | Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. ( Carroll, PR; Hricak, H; Kurhanewicz, J; Nelson, SJ; Parivar, F; Shinohara, K; Vigneron, DB, 1996) |
| "Prostate cancer is a major health problem, and the exploration of noninvasive imaging methods that have the potential to improve specificity while maintaining high sensitivity is still critically needed." | 2.44 | Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. ( Jacobs, MA; Macura, KJ; Ouwerkerk, R; Petrowski, K, 2008) |
| "When MRS and MR imaging agree on prostate cancer presence, the positive predictive value is about 80-90%." | 2.44 | Proton MR spectroscopy of the prostate. ( Mueller-Lisse, UG; Scherr, MK, 2007) |
| "Creatine treatment was associated with enhanced cellular basal respiration in vitro and increased tumor cell proliferation in vivo." | 1.72 | Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression. ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| "Fifty-seven prostate cancer patients underwent an MR examination followed by prostatectomy." | 1.43 | Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate. ( Bruggink, CC; Hambrock, T; Heerschap, A; Hulsbergen-van de Kaa, CA; Kobus, T; Maas, MC; Scheenen, TW; van der Laak, JA, 2016) |
| "Prostate cancer is common and may be treated immediately or managed conservatively by observation." | 1.40 | Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology. ( Bergen, N; Duchesne, G; Ferris, N; Frydenberg, M; Mills, J; Mitchell, C; Murphy, D; Pedersen, J; Styles, C, 2014) |
| "Gold seeds cause small effects (in the order of the standard deviation) on the ratio of the metabolite's CC/Ci in the phantom study done on a 1." | 1.38 | Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate. ( Buyyounouski, MK; Chen, L; Hossain, M; Ma, CM; Richardson, T; Schirmer, T, 2012) |
| "This supports long-term HT in advanced prostate cancer." | 1.38 | Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy. ( Bonomo, P; Clementi, V; D'Agostino, GR; Di Molfetta, IV; Gui, B; Mantini, G; Mattiucci, G; Valentini, AL, 2012) |
| "Thirty-eight patients with prostate cancer (PCa) and thirty-three patients with benign prostate hyperplasia (BPH) were included in this study." | 1.36 | 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation. ( Gao, ZQ; Liu, JG; Liu, ZQ; Niu, QL; Sun, ZK; Wang, B; Wang, XZ; Yuan, YX, 2010) |
| "In 14 prostate cancer patients who had a final pathologic Gleason scores of i) (3 + 4 = 7, n = 7) and ii) (4 + 3 = 7, n = 7), the metabolite ratios (mean +/- SD) of (Cho + Cr)/Cit and (Cho + Cr)/Spm were calculated using the 2D JPRESS spectra as follows: i) (1." | 1.36 | Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients. ( Gomez, AM; Margolis, DJ; McClure, T; Nagarajan, R; Raman, SS; Thomas, MA, 2010) |
| "Time-intensity curves were obtained for prostatic cancer and healthy PZ and CG from DCE-MRI." | 1.35 | Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. ( Bonanno, E; Carlani, M; Finazzi Agrò, E; Mancino, S; Simonetti, G, 2008) |
| " The present study aimed to clarify the utility of 11C-choline PET for localising and evaluating cancer lesions in patients with prostate cancer by conducting a prospective comparison with magnetic resonance (MR) imaging combined with proton MR spectroscopy." | 1.33 | Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. ( Endou, H; Inoue, T; Kubota, Y; Lee, J; Oka, T; Sasaki, T; Shizukuishi, K; Takahashi, N; Uemura, H; Yamaguchi, T, 2005) |
| "Dunning rat prostate cancer cells were injected into the prostate by open surgery." | 1.32 | Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. ( Fink, C; Grobholz, R; Heilmann, M; Huber, PE; Kiessling, F; Krix, M; Lichy, MP; Meding, J; Peschke, P; Schlemmer, HP, 2004) |
| "Four well-established human prostate cancer cell lines were therefore studied with magnetic resonance spectroscopy to compare differences in metabolic content with tumor biological behavior." | 1.29 | In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. ( Cornel, EB; de Ruijter, JE; Debruyne, FM; Heerschap, A; Oosterhof, GO; Schalken, JA; Smits, GA, 1995) |
| "An estimate of the spatial extent of prostate cancer was determined by generating metabolite images in which this metabolite ratio significantly exceeded normal peripheral zone values in multiple contiguous sections." | 1.29 | Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. ( Carroll, P; Hricak, H; Kurhanewicz, J; Narayan, P; Nelson, SJ; Vigneron, DB, 1996) |
| "Seven patients were diagnosed with prostate cancer, 13 with benign prostatic hypertrophy, and 3 with both conditions." | 1.28 | Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. ( Dalrymple, GV; Finkbeiner, AE; Fowler, AH; Holder, JC; Komoroski, RA; Mullins, MS; Pappas, AA; Sprigg, JR, 1992) |
| "In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer." | 1.24 | HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (12.50) | 18.7374 |
| 1990's | 6 (10.71) | 18.2507 |
| 2000's | 17 (30.36) | 29.6817 |
| 2010's | 24 (42.86) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, R | 1 |
| Ford, CA | 1 |
| Rodgers, L | 1 |
| Rushworth, LK | 1 |
| Fleming, J | 1 |
| Mui, E | 1 |
| Zhang, T | 1 |
| Watson, D | 1 |
| Lynch, V | 1 |
| Mackay, G | 1 |
| Sumpton, D | 1 |
| Sansom, OJ | 1 |
| Vande Voorde, J | 1 |
| Leung, HY | 1 |
| Reesink, DJ | 1 |
| Arteaga de Castro, CS | 1 |
| Van der Velden, T | 1 |
| Van Vooren, J | 1 |
| Oost, P | 1 |
| Jonges, TGN | 1 |
| Lam, MGEH | 1 |
| de Keizer, B | 1 |
| Willemse, PM | 1 |
| Meijer, RP | 1 |
| Klomp, DWJ | 1 |
| Fairman, CM | 1 |
| Kendall, KL | 1 |
| Newton, RU | 1 |
| Hart, NH | 1 |
| Taaffe, DR | 1 |
| Chee, R | 1 |
| Tang, CI | 1 |
| Galvão, DA | 1 |
| Mazaheri, Y | 1 |
| Shukla-Dave, A | 3 |
| Goldman, DA | 1 |
| Moskowitz, CS | 1 |
| Takeda, T | 1 |
| Reuter, VE | 3 |
| Akin, O | 1 |
| Hricak, H | 5 |
| Zhang, VY | 1 |
| Westphalen, A | 1 |
| Delos Santos, L | 1 |
| Tabatabai, ZL | 1 |
| Shinohara, K | 2 |
| Vigneron, DB | 3 |
| Kurhanewicz, J | 5 |
| Weis, J | 2 |
| Ortiz-Nieto, F | 2 |
| Ahlström, H | 2 |
| Sarkar, BK | 1 |
| Chakraborty, C | 1 |
| Sharma, AR | 1 |
| Bae, KJ | 1 |
| Sharma, G | 1 |
| Doss, GP | 1 |
| Dutta, D | 1 |
| Ding, S | 1 |
| Ganbold, B | 1 |
| Nam, JS | 1 |
| Lee, SS | 1 |
| Styles, C | 1 |
| Ferris, N | 1 |
| Mitchell, C | 1 |
| Murphy, D | 1 |
| Frydenberg, M | 1 |
| Mills, J | 1 |
| Pedersen, J | 1 |
| Bergen, N | 1 |
| Duchesne, G | 1 |
| Zbýň, Š | 1 |
| Krššák, M | 1 |
| Memarsadeghi, M | 1 |
| Gholami, B | 1 |
| Haitel, A | 1 |
| Weber, M | 1 |
| Helbich, TH | 1 |
| Trattnig, S | 1 |
| Moser, E | 1 |
| Gruber, S | 1 |
| Kobus, T | 2 |
| van der Laak, JA | 1 |
| Maas, MC | 1 |
| Hambrock, T | 2 |
| Bruggink, CC | 1 |
| Hulsbergen-van de Kaa, CA | 2 |
| Scheenen, TW | 4 |
| Heerschap, A | 5 |
| Bellomo, G | 1 |
| Marcocci, F | 1 |
| Bianchini, D | 1 |
| Mezzenga, E | 1 |
| D'Errico, V | 1 |
| Menghi, E | 1 |
| Zannoli, R | 1 |
| Sarnelli, A | 1 |
| Hlavcak, P | 1 |
| Häggman, M | 1 |
| Bergman, A | 1 |
| Thomas, MA | 3 |
| Lange, T | 1 |
| Velan, SS | 1 |
| Nagarajan, R | 2 |
| Raman, S | 1 |
| Gomez, A | 1 |
| Margolis, D | 2 |
| Swart, S | 1 |
| Raylman, RR | 1 |
| Schulte, RF | 1 |
| Boesiger, P | 1 |
| Brame, RS | 1 |
| Zaider, M | 1 |
| Zakian, KL | 2 |
| Koutcher, JA | 2 |
| Zelefsky, MJ | 1 |
| Scardino, PT | 2 |
| Wang, XZ | 1 |
| Wang, B | 1 |
| Gao, ZQ | 1 |
| Liu, JG | 1 |
| Liu, ZQ | 1 |
| Niu, QL | 1 |
| Sun, ZK | 1 |
| Yuan, YX | 1 |
| Near, J | 1 |
| Romagnoli, C | 1 |
| Bartha, R | 1 |
| Jacobs, MA | 1 |
| Ouwerkerk, R | 1 |
| Petrowski, K | 1 |
| Macura, KJ | 1 |
| Giusti, S | 1 |
| Caramella, D | 1 |
| Fruzzetti, E | 1 |
| Lazzereschi, M | 1 |
| Tognetti, A | 1 |
| Bartolozzi, C | 1 |
| Gomez, AM | 1 |
| Raman, SS | 1 |
| Margolis, DJ | 1 |
| McClure, T | 1 |
| Kirilova, A | 1 |
| Damyanovich, A | 1 |
| Crook, J | 1 |
| Jezioranski, J | 1 |
| Wallace, K | 1 |
| Pintilie, M | 1 |
| Verma, S | 1 |
| Rajesh, A | 1 |
| Fütterer, JJ | 1 |
| Turkbey, B | 1 |
| Pang, Y | 1 |
| Choyke, PL | 1 |
| Créhange, G | 2 |
| Parfait, S | 1 |
| Liegard, M | 1 |
| Maingon, P | 1 |
| Ben Salem, D | 1 |
| Cochet, A | 1 |
| Funes de la Vega, M | 1 |
| Cormier, L | 1 |
| Bonnetain, F | 1 |
| Mirjolet, C | 1 |
| Brunotte, F | 2 |
| Walker, PM | 1 |
| Klomp, DW | 1 |
| Arteaga, CS | 1 |
| van Asten, J | 1 |
| Boer, VO | 1 |
| Luijten, PR | 1 |
| García-Martín, ML | 1 |
| Adrados, M | 1 |
| Ortega, MP | 1 |
| Fernández González, I | 1 |
| López-Larrubia, P | 1 |
| Viaño, J | 2 |
| García-Segura, JM | 2 |
| Wright, AJ | 2 |
| Barentsz, JO | 1 |
| Buydens, LM | 1 |
| Hossain, M | 1 |
| Schirmer, T | 1 |
| Richardson, T | 1 |
| Chen, L | 1 |
| Buyyounouski, MK | 1 |
| Ma, CM | 1 |
| Geethanath, S | 1 |
| Baek, HM | 1 |
| Ganji, SK | 1 |
| Ding, Y | 1 |
| Maher, EA | 1 |
| Sims, RD | 1 |
| Choi, C | 1 |
| Lewis, MA | 1 |
| Kodibagkar, VD | 1 |
| Valentini, AL | 1 |
| Gui, B | 1 |
| D'Agostino, GR | 1 |
| Mattiucci, G | 1 |
| Clementi, V | 1 |
| Di Molfetta, IV | 1 |
| Bonomo, P | 1 |
| Mantini, G | 1 |
| Walker, P | 1 |
| Provent, P | 1 |
| Tizon, X | 1 |
| Duchamp, O | 1 |
| Genne, P | 1 |
| Selnaes, KM | 1 |
| Gribbestad, IS | 1 |
| Bertilsson, H | 1 |
| Wright, A | 1 |
| Angelsen, A | 1 |
| Tessem, MB | 1 |
| Yue, K | 1 |
| Marumoto, A | 1 |
| Binesh, N | 1 |
| Kaji, Y | 1 |
| Wada, A | 1 |
| Imaoka, I | 1 |
| Matsuo, M | 1 |
| Terachi, T | 1 |
| Kobashi, Y | 1 |
| Sugimura, K | 1 |
| Fujii, M | 1 |
| Maruyama, K | 1 |
| Takizawa, O | 1 |
| Mueller-Lisse, UG | 2 |
| Scherr, M | 1 |
| Eberhardt, S | 1 |
| Kleinman, S | 1 |
| Muruganandham, M | 1 |
| Sircar, K | 1 |
| Kattan, MW | 1 |
| HAHNEMANN, S | 1 |
| FRIIS, T | 1 |
| STERN, E | 2 |
| HOPKINS, CE | 2 |
| WEINER, JM | 1 |
| MARMORSTON, J | 2 |
| MARSHALL, S | 1 |
| LOMBARDO, LJ | 1 |
| MYERS, SM | 1 |
| GIERSON, H | 1 |
| Kumar, R | 1 |
| Kumar, M | 1 |
| Jagannathan, NR | 1 |
| Gupta, NP | 1 |
| Hemal, AK | 1 |
| Kiessling, F | 1 |
| Huber, PE | 1 |
| Grobholz, R | 1 |
| Heilmann, M | 1 |
| Meding, J | 1 |
| Lichy, MP | 1 |
| Fink, C | 1 |
| Krix, M | 1 |
| Peschke, P | 1 |
| Schlemmer, HP | 1 |
| Kim, DH | 1 |
| Xing, L | 1 |
| Daniel, B | 1 |
| Spielman, D | 1 |
| Yamaguchi, T | 1 |
| Lee, J | 1 |
| Uemura, H | 1 |
| Sasaki, T | 1 |
| Takahashi, N | 1 |
| Oka, T | 1 |
| Shizukuishi, K | 1 |
| Endou, H | 1 |
| Kubota, Y | 1 |
| Inoue, T | 1 |
| Hom, JJ | 1 |
| Coakley, FV | 1 |
| Simko, JP | 1 |
| Lu, Y | 1 |
| Qayyum, A | 1 |
| Westphalen, AC | 1 |
| Schmitt, LD | 1 |
| Carroll, PR | 2 |
| Scherr, MK | 1 |
| Carlani, M | 1 |
| Mancino, S | 1 |
| Bonanno, E | 1 |
| Finazzi Agrò, E | 1 |
| Simonetti, G | 1 |
| Nemoto, S | 1 |
| Rinsho, K | 1 |
| Cornel, EB | 1 |
| Smits, GA | 1 |
| de Ruijter, JE | 1 |
| Oosterhof, GO | 1 |
| Debruyne, FM | 1 |
| Schalken, JA | 1 |
| Narayan, P | 1 |
| Carroll, P | 1 |
| Nelson, SJ | 2 |
| Parivar, F | 1 |
| Mulvaney, PT | 1 |
| Stracke, ML | 1 |
| Nam, SW | 1 |
| Woodhouse, E | 1 |
| O'Keefe, M | 1 |
| Clair, T | 1 |
| Liotta, LA | 1 |
| Khaddurah-Daouk, R | 1 |
| Schiffmann, E | 1 |
| Sánchez-Chapado, M | 1 |
| Ibarburen, C | 1 |
| Angulo, JC | 1 |
| González, J | 1 |
| Rodríguez-Vallejo, JM | 1 |
| Stanka, M | 1 |
| Eltze, E | 1 |
| Semjonow, A | 1 |
| Sievert, KD | 1 |
| Maier, A | 1 |
| Pfleiderer, B | 1 |
| Fowler, AH | 1 |
| Pappas, AA | 1 |
| Holder, JC | 1 |
| Finkbeiner, AE | 1 |
| Dalrymple, GV | 1 |
| Mullins, MS | 1 |
| Sprigg, JR | 1 |
| Komoroski, RA | 1 |
| Guzzo, CE | 1 |
| Pachas, WN | 1 |
| Pinals, RS | 1 |
| Krant, MJ | 1 |
| Pitton, JS | 1 |
| Roch, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Creatine Supplementation and Resistance Training in Patients With Breast Cancer (CaRTiC Study)[NCT05878106] | 120 participants (Anticipated) | Interventional | 2024-01-08 | Not yet recruiting | |||
| Clinical Value of [18]Fluoroethylcholine Positron-Emission-Tomography Combined With Endorectal Magnetic Resonance Imaging by Software Fusion for Pre-therapeutic Staging of Prostate Cancer[NCT00520546] | Phase 3 | 44 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study[NCT00061347] | Phase 1 | 15 participants (Actual) | Interventional | 2003-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PET positive lesions (n=128) were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative and positive predictive values were determined. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
| Intervention | lesions (Number) | |||||
|---|---|---|---|---|---|---|
| True positive | False positive | True negative | False negative | Total true | Total false | |
| FEC-PET | 59 | 26 | 19 | 24 | 78 | 50 |
| Magnetic Resonance Imaging (MRI) | 40 | 27 | 18 | 43 | 58 | 70 |
| PET/MRI | 55 | 8 | 37 | 28 | 92 | 36 |
PET positive lesions in patients with Gleason >6(3+3),n=43 were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative & positive predictive values were determined. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
| Intervention | lesions (Number) | |||||
|---|---|---|---|---|---|---|
| True positive | False positive | True negative | False negative | Total true | Total false | |
| FEC-PET | 27 | 5 | 8 | 3 | 35 | 8 |
| Magnetic Resonance Imaging (MRI) | 22 | 9 | 4 | 8 | 26 | 17 |
| PET/MRI | 27 | 1 | 11 | 4 | 38 | 5 |
PET positive lesions were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. Sensitivity, specificity, accuracy, negative and positive predictive values were determined without malign lesions <=5mm. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
| Intervention | lesions (Number) | |||||
|---|---|---|---|---|---|---|
| True positive | False positive | True negative | False negative | Total true | Total false | |
| FEC-PET | 48 | 24 | 18 | 8 | 66 | 32 |
| Magnetic Resonance Imaging (MRI) | 37 | 26 | 16 | 19 | 53 | 45 |
| PET/MRI | 48 | 8 | 32 | 10 | 80 | 18 |
PET positive lesions were measured on its own and evaluated as malignant just as hypointense lesions on MRI. In PET/MRI analysis, MRI suspect lesions without FEC uptake were considered not to be malignant. PET positive lesions in central periurethral zone with inhomogenous signal intensity and sharp edges on MRI images were also considered to be benign. PET positive lesions in the peripheral zone without a hypointense correlate on MRI were considered to be malignant. At least 1 histological confirmed cancer lesion has to be detected by each of the 3 methods to be patient based true positive. (NCT00520546)
Timeframe: within < 2 weeks after PET/MRI
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| True Positive | False Positive | True Negative | False Negative | Total True | Total False | |
| [18F]Fluoroethylcholine Positron-Emission-Tomography (FEC-PET) | 36 | 1 | 0 | 1 | 36 | 2 |
| Magnetic Resonance Imaging (MRI) | 26 | 1 | 0 | 11 | 27 | 11 |
| PositronEmissionTomography/MagneticResonanceImaging (PET/MRI) | 35 | 0 | 1 | 2 | 36 | 2 |
6 reviews available for creatine and Cancer of Prostate
| Article | Year |
|---|---|
The role of metabolic imaging in radiation therapy of prostate cancer.
Topics: Aged; Biopsy; Creatine; Diagnostic Imaging; Humans; Ki-67 Antigen; Male; Metabolomics; Phosphorylcho | 2014 |
Novel biomarker for prostate cancer diagnosis by MRS.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Inositol; Magnetic Resonance Spectroscopy | 2014 |
Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.
Topics: Biomarkers, Tumor; Choline; Citrates; Contrast Media; Creatine; Diagnosis, Differential; Diffusion M | 2008 |
Prostate MRI and 3D MR spectroscopy: how we do it.
Topics: Choline; Citrates; Creatine; Diagnosis, Differential; Humans; Image Enhancement; Image Interpretatio | 2010 |
[1H magnetic resonance spectroscopy of the prostate].
Topics: Biopsy; Choline; Citrates; Creatine; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Magnetic | 2003 |
Proton MR spectroscopy of the prostate.
Topics: Biopsy; Choline; Citric Acid; Creatine; Diagnosis, Differential; Humans; Imaging, Three-Dimensional; | 2007 |
1 trial available for creatine and Cancer of Prostate
| Article | Year |
|---|---|
Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Androgen Antagonists; Body Composition; Combined Modality Therapy; Creatine; Dietary Supplemen | 2019 |
49 other studies available for creatine and Cancer of Prostate
| Article | Year |
|---|---|
Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.
Topics: Animals; Creatine; Creatinine; Disease Models, Animal; Humans; Intracellular Signaling Peptides and | 2022 |
Feasibility of clinical studies of chemical exchange saturation transfer magnetic resonance imaging of prostate cancer at 7 T.
Topics: Aged; Amides; Amines; Creatine; Feasibility Studies; Humans; Magnetic Resonance Imaging; Male; Prost | 2023 |
Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla.
Topics: Adult; Aged; Area Under Curve; Biopsy; Choline; Creatine; Diffusion Magnetic Resonance Imaging; Huma | 2019 |
MR spectroscopy of the prostate at 3T: measurements of relaxation times and quantification of prostate metabolites using water as an internal reference.
Topics: Adult; Aged; Biomarkers, Tumor; Body Water; Choline; Citric Acid; Creatine; Humans; Magnetic Resonan | 2013 |
Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology.
Topics: Adult; Aged; Biomarkers, Tumor; Choline; Creatine; Humans; Image Interpretation, Computer-Assisted; | 2014 |
Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
Topics: Adult; Aged; Algorithms; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonan | 2014 |
Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Diffusion Magnetic Resonance Imaging; Humans; Ima | 2016 |
MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification.
Topics: Algorithms; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Phantoms, | 2016 |
Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.
Topics: Adult; Aged; Biopsy; Case-Control Studies; Choline; Citric Acid; Creatine; False Negative Reactions; | 2009 |
Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.
Topics: Choline; Creatine; Epithelial Cells; Humans; Image Enhancement; Magnetic Resonance Spectroscopy; Mal | 2008 |
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.
Topics: Algorithms; Biopsy; Choline; Citric Acid; Creatine; Humans; Logistic Models; Magnetic Resonance Spec | 2009 |
1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
Topics: Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Diagnosis, C | 2010 |
Reduced power magnetic resonance spectroscopic imaging of the prostate at 4.0 Tesla.
Topics: Adult; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Electromagnetic Fields; Humans; Magnetic R | 2009 |
Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D ¹H MR spectroscopic imaging: correlation with pathologic findings.
Topics: Aged; Biopsy; Choline; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy | 2010 |
Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients.
Topics: Aged; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pr | 2010 |
3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
Topics: Brachytherapy; Choline; Citric Acid; Creatine; Humans; Iodine Radioisotopes; Magnetic Resonance Imag | 2011 |
Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.
Topics: Aged; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Ma | 2011 |
Detection of fully refocused polyamine spins in prostate cancer at 7 T.
Topics: Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Po | 2011 |
Quantitative (1) H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings.
Topics: Adenocarcinoma; Choline; Citric Acid; Creatine; Humans; In Vitro Techniques; Magnetic Resonance Spec | 2011 |
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Choline; Citric Acid; Creatine; Equipment Design; Humans; Ma | 2011 |
A phase and frequency alignment protocol for 1H MRSI data of the prostate.
Topics: Algorithms; Choline; Citric Acid; Computer Simulation; Creatine; Databases, Factual; Humans; Magneti | 2012 |
Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate.
Topics: Biomarkers; Choline; Citrates; Creatine; Fiducial Markers; Gold; Humans; Magnetic Resonance Spectros | 2012 |
Compressive sensing could accelerate 1H MR metabolic imaging in the clinic.
Topics: Algorithms; Analysis of Variance; Aspartic Acid; Brain Neoplasms; Choline; Citric Acid; Creatine; Da | 2012 |
Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Choline; Combined Moda | 2012 |
In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T.
Topics: Animals; Cell Line, Tumor; Choline; Creatine; Humans; Inositol; Magnetic Resonance Imaging; Magnetic | 2013 |
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.
Topics: Aged; Aged, 80 and over; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Ma | 2013 |
2D JPRESS of human prostates using an endorectal receiver coil.
Topics: Adult; Biomarkers, Tumor; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; M | 2002 |
Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil.
Topics: Adult; Aged; Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance | 2002 |
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results.
Topics: Choline; Citric Acid; Creatine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; | 2003 |
[REABSORPTION OF PHOSPHORUS IN THE RENAL TUBULES IN NONPARATHYROGENOUS DISEASES].
Topics: Adenoma; Bone Neoplasms; Breast Neoplasms; Creatine; Creatinine; Denmark; Diagnosis, Differential; H | 1964 |
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine | 1964 |
UREA-CREATININE RATIO IN OBSTRUCTIVE UROPATHY AND RENAL HYPERTENSION.
Topics: Acute Kidney Injury; Blood; Blood Urea Nitrogen; Creatine; Creatinine; Humans; Hypertension, Renal; | 1964 |
URINARY EXCRETION OF NEUTRAL 17-KETOSTEROIDS AND PREGNANEDIOL BY PATIENTS WITH PROSTATIC CANCER AND BENIGN PROSTATIC HYPERTROPHY.
Topics: 17-Ketosteroids; Androsterone; Blood Glucose; Blood Urea Nitrogen; Creatine; Creatinine; Etiocholano | 1965 |
Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Choline; Citric Acid; Creatine; Diagnosis, Differential; | 2004 |
Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy.
Topics: Animals; Antigens, CD34; Choline; Creatine; Disease Models, Animal; Immunohistochemistry; Magnetic R | 2004 |
In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-resolved PRESS at 3 T.
Topics: Choline; Citrates; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Phantoms, Imaging; Prost | 2005 |
Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.
Topics: Aged; Biopsy; Carbon Radioisotopes; Choline; Citrates; Creatine; Humans; Magnetic Resonance Spectros | 2005 |
High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
Topics: Aged; Cell Nucleus; Cell Nucleus Size; Choline; Citric Acid; Cohort Studies; Creatine; Humans; Image | 2007 |
Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.
Topics: Aged; Choline; Citric Acid; Contrast Media; Creatine; Gadolinium; Humans; Image Processing, Computer | 2008 |
[Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Creatine; Humans; Hydroxyproline; Male; | 1984 |
In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines.
Topics: Androgens; Citrates; Citric Acid; Creatine; Humans; Magnetic Resonance Spectroscopy; Male; Perchlora | 1995 |
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
Topics: Adenocarcinoma; Adult; Aged; Choline; Citrates; Citric Acid; Creatine; Diagnosis, Differential; Huma | 1996 |
Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
Topics: Aged; Choline; Citrates; Citric Acid; Creatine; Cryosurgery; Humans; Magnetic Resonance Imaging; Mag | 1996 |
Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Topics: Antineoplastic Agents; Cell Movement; Chemotaxis; Cisplatin; Creatine; Creatine Kinase; Creatinine; | 1998 |
In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
Topics: Aged; Aged, 80 and over; Choline; Citric Acid; Creatine; Diagnosis, Differential; Humans; Inositol; | 1999 |
[Spectroscopic imaging (1H-2D-CSI) of the prostate: sequence optimization and correlation with histopathological results].
Topics: Aged; Choline; Citrates; Creatine; Diagnosis, Differential; Humans; Magnetic Resonance Spectroscopy; | 2000 |
Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR.
Topics: Alanine; Citrates; Creatine; Glutamates; Glutamic Acid; Humans; In Vitro Techniques; Magnetic Resona | 1992 |
Urinary hydroxyproline excretion in patients with cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Creatine; Female; Humans; | 1969 |
Serum levels of methacycline.
Topics: Adult; Aged; Biological Assay; Blood Urea Nitrogen; Bronchopneumonia; Cachexia; Cerebrovascular Diso | 1966 |